VivoSeq
Oncology

Carcinoid Tumor

27

Pipeline Programs↗

2

Active Trials↗

18

Companies Involved↗

Carcinoid Tumor is an emerging landscape with 27 programs across 18 companies. The most active players are Bristol-Myers Squibb, Regeneron, CASI Pharmaceuticals, Inc.. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

0/100

Mech. Concentration

15/100

Completion Rate

83/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 2Regeneron logo

Regeneron

2 programs

Phase 2C

CASI Pharmaceuticals, Inc.

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2Eisai logo

Eisai

1 program

Phase 2A

Albireo, an Ipsen Company

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

64%

Small molecule

16 of 25 classified programs — the dominant modality here.

36%ALL OTHERSPeptide416%Monoclonal antibody312%Protein / enzyme28%

Small molecule leads; the ring shows all 25 classified programs, each share of the total. Modality classified for 100% of 27 pipeline programs.

Analysis

Trial Status

15

clinical trials

Completed10 · 67%
Active, not recruiting2 · 13%
Withdrawn2 · 13%
Unknown status1 · 7%

Clinical Trials

Trial Activity

15 trials

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03950609·36 enrolled
Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03110978·140 enrolled
Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors
Completed·—·Phase 2·NCT01782443·19 enrolled
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
Completed·National Cancer Institute (NCI)·Phase 2·NCT00055809·44 enrolled
A Study of Axitinib in Advanced Carcinoid Tumors
Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01435122·30 enrolled
A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid Tumors
Completed·CCASI Pharmaceuticals, Inc.·Phase 2·NCT00328497·31 enrolled
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Completed·—·Phase 2·NCT01466036·61 enrolled
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Completed·Novartis logoNovartis·Phase 3·NCT00412061·429 enrolled
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Completed·Novartis logoNovartis·Phase 2·NCT00088595·45 enrolled
Cabozantinib and Nivolumab for Carcinoid Tumors
Completed·—·Phase 2·NCT04197310·19 enrolled
Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors
Completed·MMid-Atlantic Oncology Program·Phase 2·NCT00002470
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Completed·—·Phase 2·NCT02795858·43 enrolled
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
Withdrawn·MMassachusetts General Hospital·Phase 1·NCT03057509
Study to Evaluate the Efficacy and Safety of 90Y-SMT487 in Subjects With Symptomatic Malignant Carcinoid Tumors
Withdrawn·MMolecular Insight Pharmaceuticals, Inc.·Phase 2·NCT00696930
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
Unknown status·GERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT01731925·44 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)